Item 2.02. Results of Operations and Financial Condition.

On November 9, 2021, ClearPoint Neuro, Inc. (the "Company") issued a press release announcing its financial performance for the third fiscal quarter ended September 30, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On November 9, 2021, the Company posted an updated investor presentation to its website at http://ir.stockpr.com/clearpointneuro/investor-presentations. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.




 Item  9.01 Financial Statements and Exhibits.




(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit 99.1 Press Release dated November 9, 2021

Exhibit 99.2 Investor Presentation dated November 2021

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses